miR-16 rescues F508del-CFTR function in native cystic fibrosis epithelial cells

Kumar, Pravin; Bhattacharyya, Somnath; Peters, Kathryn W.; Glover, M L; Sen, Aditya; Cox, Rachel T.; Kundu, Samrat T.; Caohuy, Hung; Frizzell, Raymond A.; Pollard, Harvey B.; Biswas, Roopa

doi:10.1038/gt.2015.56

Cited by 21 publications

(15 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Numerous miRNAs had altered expression between CF and non-CF bronchial epithelium, and some of the altered miRNAs were predicted to regulate CFTR. Various other published studies have examined the role of miRNAs in the direct or indirect control of wild type (wt) or mutant CFTR expression [41][42][43][45][46][47][48][49][50].…”

Section: Other Mechanisms Affecting Cftr Expression In Cfmentioning

confidence: 99%

CFTR dysfunction in cystic fibrosis and chronic obstructive pulmonary disease

Fernández

Santi

Rose

et al. 2018

Expert Review of Respiratory Medicine

View full text Add to dashboard Cite

Obstructive lung diseases such as cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD) are causes of high morbidity and mortality worldwide. CF is a multiorgan genetic disease caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene and is characterized by progressive chronic obstructive lung disease. Most cases of COPD are a result of noxious particles, mainly cigarette smoke but also other environmental pollutants. Areas covered: Although the pathogenesis and pathophysiology of CF and COPD differ, they do share key phenotypic features and because of these similarities there is great interest in exploring common mechanisms and/or factors affected by CFTR mutations and environmental insults involved in COPD. Various molecular, cellular and clinical studies have confirmed that CFTR protein dysfunction is common in both the CF and COPD airways. This review provides an update of our understanding of the role of dysfunctional CFTR in both respiratory diseases. Expert commentary: Drugs developed for people with CF to improve mutant CFTR function and enhance CFTR ion channel activity might also be beneficial in patients with COPD. A move toward personalized therapy using, for example, microRNA modulators in conjunction with CFTR potentiators or correctors, could enhance treatment of both diseases.

show abstract

Section: Other Mechanisms Affecting Cftr Expression In Cfmentioning

confidence: 99%

CFTR dysfunction in cystic fibrosis and chronic obstructive pulmonary disease

Fernández

Santi

Rose

et al. 2018

Expert Review of Respiratory Medicine

View full text Add to dashboard Cite

show abstract

“…Interestingly, miR-138 and SIN3A were both shown to control a subset of genes and pathways important for wild type and mutant CFTR biogenesis. Moreover, miR-16 was shown to rescue the trafficking defects of F508del CFTR, likely through suppression of Heat shock protein 90 (HSP90), a chaperone involved in protein-folding activity (Kumar et al, 2015). We recently characterized a novel microRNA, miR-1343, that represses the receptors for transforming growth factor beta (TGF-β), a cytokine involved in wound-healing responses.…”

Section: Cystic Fibrosismentioning

confidence: 99%

The role of microRNAs in chronic respiratory disease: recent insights

Stolzenburg¹,

Harris²

2017

Biological Chemistry

View full text Add to dashboard Cite

Chronic respiratory diseases encompass a group of diverse conditions affecting the airways, which all impair lung function over time. They include cystic fibrosis (CF), idiopathic pulmonary fibrosis (IPF), chronic obstructive pulmonary disease (COPD) and asthma, which together affect hundreds of millions of people worldwide. MicroRNAs (miRNAs), a class of small non-coding RNAs involved in post-transcriptional gene repression, are now recognized as major regulators in the development and progression of chronic lung disease. Alterations in miRNA abundance occur in lung tissue, inflammatory cells, and freely circulating in blood and are thought to function both as drivers and modifiers of disease. Their importance in lung pathology has prompted the development of miRNA-based therapies and biomarker tools. Here, we review the current literature on miRNA expression and function in chronic respiratory disease and highlight further research that is needed to propel miRNA treatments for lung disorders towards the clinic.

show abstract

“…This has been observed by Amato et al who found that the CFTR polymorphism (rs10234329) enhances the affinity for miR-509-3p, a potential CFTR transcript modulator [ 64 ]. Moreover, miR-16 was discovered to restore the deltaF508 CFTR protein function by regulating the cAMP-activated chloride conductance and by reducing the IL-8 expression [ 65 ].…”

Section: Ncrna Studies In Cystic Fibrosismentioning

confidence: 99%

Non-Coding RNAs in Pediatric Airway Diseases

Narożna

Langwiński

Szczepankiewicz

2017

Genes

View full text Add to dashboard Cite

Non-coding RNAs (ncRNAs) are involved in the regulation of numerous biological processes and pathways and therefore have been extensively studied in human diseases. Previous reports have shown that non-coding RNAs play a crucial role in the pathogenesis and aberrant regulation of respiratory diseases. The altered expression of microRNAs (miRNAs) and long non-coding RNAs in blood and also locally in sputum or exhaled breath condensate influences lung function, immune response, and disease phenotype and may be used for the development of biomarkers specific for airway disease. In this review, we provide an overview of the recent works studying the non-coding RNAs in airway diseases, with a particular focus on chronic respiratory diseases of childhood. We have chosen the most common chronic respiratory condition—asthma—and the most severe, chronic disease of the airways—cystic fibrosis. Study of the altered expression of non-coding RNAs in these diseases may be key to better understanding their pathogenesis and improving diagnosis, while also holding promise for the development of therapeutic strategies using the regulatory potential of non-coding RNAs.

show abstract

miR-16 rescues F508del-CFTR function in native cystic fibrosis epithelial cells

Cited by 21 publications

References 31 publications

CFTR dysfunction in cystic fibrosis and chronic obstructive pulmonary disease

CFTR dysfunction in cystic fibrosis and chronic obstructive pulmonary disease

The role of microRNAs in chronic respiratory disease: recent insights

Non-Coding RNAs in Pediatric Airway Diseases

Contact Info

Product

Resources

About